real-time news and commentary for investors
Monday, Jul 30
2012, 11:43 AM
Arena (ARNA) transfers the marketing rights for its Belviq diet drug to partner Eisai...
Arena (ARNA) transfers the marketing rights for its Belviq diet drug to partner Eisai (ESALY.PK), which will market the pill in the U.S. and apply for authorization in other countries in the Americas. SA author Red Acre Investments notes that what is not explicitly stated is that Eisai, not Arena, will run all of the pediatric and cardiovascular outcome trials that are required under Belviq's FDA approval letter (.pdf). (PR)